A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
Part One Of A Two-Part Interview With NCI Director Harold Varmus
Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
Richard Pazdur’s Comments to ODAC
Department of Defense Offering $16 Million in Cancer Research Grants
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
